Dr. Eisenberger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231Phone+1 410-614-3511- Is this information wrong?
Summary
- Professor of Oncology and Urology
Education & Training
- University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1976 - 1978
- Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1973 - 1975
- Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1972
- Brazil-American CollegeB.S., Cum Laude, 1965 - 1966
- Mello E. Souza CollegeNo Degree, 1963 - 1965
Certifications & Licensure
- MD State Medical License 1982 - 2024
- PA State Medical License 2020 - 2022
- DC State Medical License 2012 - 2020
- IL State Medical License 1975 - 1980
- FL State Medical License 1978 - 1979
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Prostate Cancer Challenge Award Prostate Cancer Foundation, 2015
- America's Top Doctors Castle Connolly, 2003-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Join now to see all
Clinical Trials
- Study of Individualized Amonafide to Treat Prostate Cancer Start of enrollment: 2004 Mar 01
- Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer Start of enrollment: 2006 Jul 20
- Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 2004 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.Lalji, A., Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Pall...> ;Nature Communications. 2024 Jan 2
- Test-retest repeatability of organ uptake on PSMA-targetedF-DCFPyL PET/CT in patients with prostate cancer.Rudolf A Werner, Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K Buck, Aleksander Kosmala, Constantin Lapa, Markus Essler, Martin A Lodge, Ke...> ;The Prostate. 2023 Sep 1
- Multi-timepoint imaging with PSMA-targeted [F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging.Sara Sheikhbahaei, Ricardo Bello Martinez, Mark C Markowski, Mario A Eisenberger, Kenneth J Pienta, Diane Reyes, Mary Katherine Brosnan, Ergi Spiro, Rehab AbdAllah, Da...> ;Annals of Nuclear Medicine. 2023 Apr 1
- Join now to see all
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
- Original Contribution TP53 Missense Mutation Is Associated with Increased Tumor-Infiltrating T-cells in Primary Prostate Cancer☆Tamara L Lotan, Mario Eisenberger, Harsimar B Kaur, Scott A Tomlins, Edward M Schaeffer, ScienceDirect
- Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years Progress with AntiandrogensCrawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F, The Journal of Urology, 1/1/2018
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.V.J. Sinibaldi, M. Dadon-Nachum, M. Gottfried, N. Maimon, Z. Dovrish, A. Peer, A. Neumann, A. Sella, S. Kovel, M.A. Carducci, M.A. Eisenberger, D. Keizman, Genitourinary Cancers Symposium, 1/1/2014
- A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).M.T. Schweizer, E.S. Antonarakis, H. Wang, A.N. Spitz, H.Cao, A. Pacheo, M.A. Eisenberger, M.A. Carducci, S.R. Denmeade, Genitourinary Cancers Symposium, 1/1/2014
- A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer.C.J. Paller, M.A. Rudek, E.S. Antonarakis, M.A. Eisenberger, H.J. Hammers, X.C. Zhou, D. Dowling, S. King, S. Hudock, S.R. Denmeade, W.D. Wagner, G.L. Rosner, T. Hudso..., Genitourinary Cancers Symposium, 1/1/2014
- Join now to see all
Lectures
- Selected Aspects in the management and treatment of Relapsed Prostate Cancer.University of Maryland Cancer Center - 1/1/2016
- Advances in Hormonal therapy for prostate cancer and optimal timing for androgen deprivation.1/1/2016
- Biomarkers in Prostate CancerBoston, MA - 1/1/2015
- Join now to see all
Other
- Chemotherapy for prostate cancer.Eisenberger MA, Plenary Session Debate-European Association of Urology
Milan, Italy - 1/1/2007 - Therapeutic strategies for patients with a rising PSA: A case-based approach. Report to the Nation on Prostate Cancer 2004.D'Amico AV, Eisenberger MA, Partin AW, Pienta KJ, Prostate Cancer Foundation (pp. 85-92)
1/1/2004 - Hormonal Therapy for Advanced Prostate Cancer.Eisenberger, M, The Johns Hopkins White Paper Bulletins, Prostate Bulletin Winter Issue (pp. 23-32)
1/23/2002 - Join now to see all
Press Mentions
- Reduced-Dose Cabazitaxel Shows Efficacy in mCRPCAugust 25th, 2017
- The Female Health Company and Aspen Park Pharmaceuticals Name Members of New Board of Directors, to Serve Upon Completion of MergerAugust 11th, 2016
- Localized Prostate CancerJune 13th, 2018
Other Languages
- German, Portuguese, Spanish
Hospital Affiliations
- Johns Hopkins HospitalBaltimore, Maryland
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/mario-eisenberger
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: